DS002
DS002 is a human monoclonal antibody targeting NGF/bNGF, with an IC50 of 6.60 nM against human NGF, 1.98 nM against rat NGF, and 8.46 nM against mouse NGF. DS002 blocks NGF-TrkA binding, interrupts pain signal transduction, inhibits TrkA-mediated downstream signaling pathways, and alters aromatic amino acid metabolic pathways. DS002 inhibits cancer cell proliferation. DS002 exerts a preventive effect on Paclitaxel-, Cisplatin- and Vincristine-induced peripheral neuropathy in rats. DS002 can be used in studies related to chronic pain and chemotherapy-induced peripheral neuropathy.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Species Reactivity
Human
IC50 & Target
[2]|
TrkA |
体外実験
DS002 potently blocks the binding of human NGF to TrkA in cell-free competitive ELISA assays, with an IC50 of 6.6 nM[2].
DS002 (0.001-100 nM) binds to human, rat and mouse NGF with high affinity in cell-free ELISA assays, with corresponding EC50 values of 0.031 nM, 0.086 nM and 0.036 nM[2].
DS002 (1.5625-100 nM) exhibits ultrahigh binding affinity (KD <1 pM) for human NGF and high binding affinity (KD values of 149 pM and 582 pM, respectively) for rat and mouse NGF in cell-free BLI assays[2].
DS002 potently blocks the binding of rat and mouse NGF to TrkA in cell-free competitive ELISA assays, with IC50 values of 1.98 nM and 8.46 nM, respectively[2].
DS002 inhibits NGF-induced TF-1 cell proliferation in a dose-dependent manner by blocking the TrkA-mediated downstream signaling pathway in cell-based in vitro assays[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
DS002 (0.02-0.5 mg/kg; subcutaneous injection; administered on days -3 to 16) exerts a significant preventive effect against Cisplatin (HY-17394)-induced mechanical hyperalgesia in rats[2].
DS002 (0.5-2.5 mg/kg; subcutaneous injection; administered on days -3 to 3) exerts a significant preventive effect on mechanical and cold allodynia induced by Vincristine (HY-N0488A) in rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (SD) (male, 200-220 g starting weight, paclitaxel-induced CIPN model)[2]
-
Dosage:0.1 mg/kg; 0.5 mg/kg; 2.5 mg/kg
-
Administration:s.c.; administered on days -3, 3, 9
-
Result:Increased paw withdrawal threshold (PWT) significantly compared to vehicle control on day 14.
Decreased acetone-induced pain scores and foot withdrawal frequency drastically compared to vehicle control on day 15 (0.5 mg/kg and 2.5 mg/kg doses).
Caused no weight loss in treated rats.
-
Animal Model:Sprague-Dawley (SD) (male, 200-220 g starting weight, cisplatin-induced CIPN model)[2]
-
Dosage:0.02 mg/kg; 0.5 mg/kg
-
Administration:s.c.; administered on days -3, 3, 9, 16
-
Result:Increased paw withdrawal threshold (PWT) significantly compared to vehicle control on day 21.
Showed no analgesic effect on cold allodynia due to unsuccessful model establishment.
Caused no weight loss in treated rats.
-
Animal Model:Sprague-Dawley (SD) (male, 200-220 g starting weight, vincristine-induced CIPN model)[2]
-
Dosage:0.1 mg/kg; 0.5 mg/kg; 2.5 mg/kg
-
Administration:s.c.; administered on days -3, 3
-
Result:Increased paw withdrawal threshold (PWT) significantly compared to vehicle control on day 7 (0.5 mg/kg and 2.5 mg/kg doses).
Reduced acetone-induced pain scores and foot withdrawal frequency compared to vehicle control on day 8 (0.5 mg/kg and 2.5 mg/kg doses).
Caused no weight loss in treated rats.
- BrdU Incorporation Assay
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- PC12 NGF-induced neuronal-like differentiation
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Cell Viability Determination by MTT Colorimetric Assay
- PC12 NGF-Induced Neuronal Differentiation Culture
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- MTT Cell Proliferation Assay
遺伝子ID
アクセッション番号
Target
NGF/bNGF
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
アプリケーション
ELISA, FACS, Functional assay
化学情報
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Jin D, et al. Effect of the novel anti-NGF monoclonal antibody DS002 on the metabolomics of pain mediators, cartilage and bone. Front Pharmacol. 2024;15:1396790. Published 2024 Aug 12. [Content Brief]
[2]. Liang ZJ, et al. NGF monoclonal antibody DS002 alleviates chemotherapy-induced peripheral neuropathy in rats. Acta Pharmacol Sin. 2022;43(11):2841-2847. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
DS002 関連分類
HY-P992345 関連分類
Powered by Bioz